Zobrazeno 1 - 10
of 320
pro vyhledávání: '"Murumägi A"'
Autor:
Piki, Emilia, Dini, Alice, Rantanen, Frida, Bentz, Franziska, Paavolainen, Lassi, Barker, Harlan, Raivola, Juuli, Hirasawa, Akira, Kallioniemi, Olli, Murumägi, Astrid, Ungureanu, Daniela
Publikováno v:
In Molecular Therapy: Oncology November 2024
Autor:
Emilia Piki, Alice Dini, Juuli Raivola, Kari Salokas, Kaiyang Zhang, Markku Varjosalo, Teijo Pellinen, Katja Välimäki, Kristina Tabor Veskimäe, Synnöve Staff, Sampsa Hautaniemi, Astrid Murumägi, Daniela Ungureanu
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Wnt pathway dysregulation through genetic and non-genetic alterations occurs in multiple cancers, including ovarian cancer (OC). The aberrant expression of the non-canonical Wnt signaling receptor ROR1 is thought to contribute to OC progress
Externí odkaz:
https://doaj.org/article/a88f0a5d9ef74d3ba66b390c6a8db639
Autor:
Michaela Feodoroff, Piia Mikkonen, Laura Turunen, Antti Hassinen, Lauri Paasonen, Lassi Paavolainen, Swapnil Potdar, Astrid Murumägi, Olli Kallioniemi, Vilja Pietiäinen
Publikováno v:
SLAS Discovery, Vol 28, Iss 4, Pp 138-148 (2023)
Central to the success of functional precision medicine of solid tumors is to perform drug testing of patient-derived cancer cells (PDCs) in tumor-mimicking ex vivo conditions. While high throughput (HT) drug screening methods have been well-establis
Externí odkaz:
https://doaj.org/article/bdeaf7bd18484cce910d529df5e05a9f
Autor:
Michaela Feodoroff, Piia Mikkonen, Mariliina Arjama, Astrid Murumägi, Olli Kallioniemi, Swapnil Potdar, Laura Turunen, Vilja Pietiäinen
Publikováno v:
SLAS Discovery, Vol 28, Iss 2, Pp 36-41 (2023)
Establishment of drug testing of patient-derived cancer cells (PDCs) in physiologically relevant 3-dimensional (3D) culture is central for drug discovery and cancer research, as well as for functional precision medicine. Here, we describe the detaile
Externí odkaz:
https://doaj.org/article/a216792f7fee4734a2a5689901736c51
Autor:
Feodoroff, Michaela, Mikkonen, Piia, Turunen, Laura, Hassinen, Antti, Paasonen, Lauri, Paavolainen, Lassi, Potdar, Swapnil, Murumägi, Astrid, Kallioniemi, Olli, Pietiäinen, Vilja
Publikováno v:
In SLAS Discovery June 2023 28(4):138-148
Autor:
Ollila-Raj, Hely, Murumägi, Astrid, Pellinen, Teijo, Arjama, Mariliina, Sutinen, Eva, Volmonen, Kirsi, Haikala, Heidi M., Kallioniemi, Olli, Mäyränpää, Mikko I., Ilonen, Ilkka
Publikováno v:
In Lung Cancer April 2023 178:213-219
Autor:
Juuli Raivola, Alice Dini, Hanna Karvonen, Emilia Piki, Kari Salokas, Wilhelmiina Niininen, Laura Kaleva, Kaiyang Zhang, Mariliina Arjama, Greta Gudoityte, Brinton Seashore-Ludlow, Markku Varjosalo, Olli Kallioniemi, Sampsa Hautaniemi, Astrid Murumägi, Daniela Ungureanu
Publikováno v:
Cell Death and Disease, Vol 13, Iss 8, Pp 1-12 (2022)
Abstract Most patients with ovarian cancer (OC) are diagnosed at a late stage when there are very few therapeutic options and a poor prognosis. This is due to the lack of clearly defined underlying mechanisms or an oncogenic addiction that can be tar
Externí odkaz:
https://doaj.org/article/47baa86ead214039b8cd980a88935c5f
Autor:
Ammad-ud-din, Muhammad, Khan, Suleiman A., Malani, Disha, Murumägi, Astrid, Kallioniemi, Olli, Aittokallio, Tero, Kaski, Samuel
Publikováno v:
2016 Bioinformatics Published by Oxford University Press
A key goal of computational personalized medicine is to systematically utilize genomic and other molecular features of samples to predict drug responses for a previously unseen sample. Such predictions are valuable for developing hypotheses for selec
Externí odkaz:
http://arxiv.org/abs/1606.03623
Autor:
Laura Kohtamäki, Mariliina Arjama, Siru Mäkelä, Philipp Ianevski, Katja Välimäki, Susanna Juteau, Suvi Ilmonen, Daniela Ungureanu, Olli Kallioniemi, Astrid Murumägi, Micaela Hernberg
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101290- (2022)
Therapy options for patients with metastatic melanoma (MM) have considerably improved over the past decade. However, many patients still need effective therapy after unsuccessful immunotherapy, especially patients with BRAF-negative tumors who lack t
Externí odkaz:
https://doaj.org/article/eb0a34765eab4df0b6fe28e9b642ca47
Autor:
Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M. Haikala, Olli Kallioniemi, Mikko I. Mäyränpää, Ilkka Ilonen
Publikováno v:
Lung Cancer. 178:213-219
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6a32e1ebed5f3fed839f13126e1fe99
https://doi.org/10.1016/j.lungcan.2023.02.024
https://doi.org/10.1016/j.lungcan.2023.02.024